VDYNE

MAPLE GROVE, MINN., USA, January 6, 2021 /EINPresswire.com/ -- VDYNE, Inc. ("VDYNE" or “the Company”), a privately held medical device company developing technologies for the treatment of tricuspid regurgitation, announced today that it has secured a $21M Series C financing. The financing round was supported by strong participation from existing investors, including Jean Boulle Medtech, together with significant participation from a large, global medical device company.

VDYNE’s innovative technology addresses tricuspid valve regurgitation, a condition whereby the heart can become enlarged due to impaired functionality of the tricuspid valve. The right ventricle’s primary responsibility is to pump blood from the heart to the lungs for re-oxygenation, and eventual recirculation to the body. However, if the tricuspid valve does not close properly during ventricle contraction, then blood flows back or “leaks” from the right ventricle into the right atrium leading to shortness of breath, fatigue, abnormal heart performance and a potentially enlarged heart.

VDYNE’s novel valve replacement and minimally invasive delivery system enables the treatment of a broad range of tricuspid anatomies. VDYNE’s unique system delivers a prosthetic valve via a transfemoral catheter, and is completely repositionable and retrievable. The Company is nearing completion of requisite pre-clinical studies and the proceeds from the financing will support the Company’s first-in-human feasibility studies which are expected to commence in the first half 2021.

“The financing is a significant milestone for VDYNE and we warmly welcome a large, global medical device company to our investor base. We are moving very quickly in our pre-clinical efforts and are looking forward to the commencement of human feasibility studies in the new year” commented Jean Raymond Boulle II, Director of both VDYNE and Jean Boulle MedTech.

About VDYNE Inc

VDYNE is a privately held medical device company pioneering an innovative interventional valve replacement technology for the treatment of tricuspid regurgitation. VDYNE is based in Maple Grove, Minneapolis.

The VDYNE tricuspid valve replacement system is under clinical investigation and is not commercially available in the United States of America, or elsewhere.

 
About Tricuspid Regurgitation

Tricuspid regurgitation occurs when the tricuspid valve does not close properly, blood flows backwards from the right ventricle into the right atrium instead of progressing to the heart for re-oxygenation. This regurgitation is a debilitating condition that impacts the general health and quality of life of a significant portion of the patient population. More importantly, surgical intervention to treat tricuspid regurgitation has high rates of mortality and morbidity. There are presently no approved minimally invasive valve replacement treatment alternatives.

For more information please contact:

Lauren Farrell at lfarell@vdyne.com

Andrew Mills
Aura Financial
+44 20 7321 0000
info@aura-financial.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.